Edition:
United States

Aldeyra Therapeutics Inc (ALDX.OQ)

ALDX.OQ on NASDAQ Stock Exchange Capital Market

8.00USD
12:56pm EDT
Change (% chg)

$-0.05 (-0.62%)
Prev Close
$8.05
Open
$8.05
Day's High
$8.05
Day's Low
$7.85
Volume
3,855
Avg. Vol
27,734
52-wk High
$11.90
52-wk Low
$3.90

Latest Key Developments (Source: Significant Developments)

Aldeyra Therapeutics Announces Agreement With Johnson & Johnson Innovation To Advance Novel Immune-Modulating Drugs
Tuesday, 27 Feb 2018 08:00am EST 

Feb 27 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS ANNOUNCES AGREEMENT WITH JOHNSON & JOHNSON INNOVATION TO ADVANCE NOVEL IMMUNE-MODULATING DRUGS FOR SYSTEMIC INFLAMMATORY DISEASES.ALDEYRA THERAPEUTICS INC - ‍ ENTERED INTO A COLLABORATIVE RESEARCH AGREEMENT WITH JANSSEN RESEARCH & DEVELOPMENT​.ALDEYRA - ‍ AGREEMENT WITH JANSSEN TO ADVANCE DEVELOPMENT OF EXISTING ANALOGS OF REPROXALAP FOR TREATMENT OF SYSTEMIC INFLAMMATORY DISEASES​.ALDEYRA THERAPEUTICS INC - WILL COLLABORATE WITH JANSSEN ON RESEARCH ACTIVITIES, WHICH WILL BE GOVERNED BY A JOINT SCIENTIFIC REVIEW COMMITTEE​.ALDEYRA - ‍ FOR A LIMITED PERIOD, SUBJECT TO CONDITIONS, JANSSEN TO RETAIN OPTION TO NEGOTIATE EXCLUSIVE LICENSE PERTAINING TO COMPOUNDS DEVELOPED.  Full Article

Aldeyra Therapeutics Posts Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data
Wednesday, 29 Nov 2017 08:00am EST 

Nov 29 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS PRESENTS NONINFECTIOUS ANTERIOR UVEITIS PHASE 2 CLINICAL TRIAL DATA TO THE AMERICAN UVEITIS SOCIETY HELD AT THE AMERICAN ACADEMY OF OPHTHALMOLOGY 2017 ANNUAL MEETING.  Full Article

Aldeyra Therapeutics reports Q3 loss per share of $0.32
Thursday, 9 Nov 2017 07:30am EST 

Nov 9 (Reuters) - Aldeyra Therapeutics Inc :Aldeyra Therapeutics announces third quarter 2017 financial results.Q3 loss per share $0.32.Q3 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S.‍Cash, cash equivalents, and marketable securities were $47.9 million as of September 30, 2017​.  Full Article

Aldeyra ‍announcesd new data for ADX-102 from Phase 2 clinical trials
Tuesday, 10 Oct 2017 07:30am EDT 

Oct 10 (Reuters) - Aldeyra Therapeutics Inc :Aldeyra - ‍announced new clinical data for ADX-102 from recently completed Phase 2 clinical trials of dry eye disease and allergic conjunctivitis​.Aldeyra Therapeutics Inc - ‍Aldeyra plans to commence phase 2B clinical testing of ADX-102 in dry eye disease in first half of 2018​.Aldeyra Therapeutics Inc - ‍ADX-102 generated clinically important responses statistically superior to vehicle in patients with allergic conjunctivitis​.Aldeyra Therapeutics Inc - ‍plans to commence Phase 3 clinical testing of ADX-102 in allergic conjunctivitis in first half of 2018​.  Full Article

Aldeyra Therapeutics posts pricing of public offering of common stock
Tuesday, 19 Sep 2017 08:57am EDT 

Sept 19 (Reuters) - Aldeyra Therapeutics Inc :Aldeyra Therapeutics Inc announces pricing of public offering of common stock.Says public offering of 3.45 mln common shares priced at $7.25 per share.  Full Article

Aldeyra Therapeutics announces proposed public offering of common stock
Monday, 18 Sep 2017 04:01pm EDT 

Sept 18 (Reuters) - Aldeyra Therapeutics Inc :Aldeyra Therapeutics Inc announces proposed public offering of common stock.Aldeyra Therapeutics - To offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering​.Aldeyra Therapeutics Inc says ‍net proceeds to be used for continued development of Aldeyra's lead compound ADX-102 and other product candidates​.  Full Article

Aldeyra Therapeutics announces positive results from dry eye disease phase 2a clinical trial
Tuesday, 12 Sep 2017 07:01am EDT 

Sept 12 (Reuters) - Aldeyra Therapeutics Inc ::Aldeyra Therapeutics announces positive results from dry eye disease phase 2a clinical trial.Aldeyra Therapeutics says statistically and clinically significant improvement across multiple sign and symptom endpoints for ADX-102.Aldeyra Therapeutics says no safety concerns observed for any of the formulations of ADX-102, no serious adverse events were reported.Aldeyra Therapeutics says look forward to initiation of phase 2b clinical trial in dry eye disease in H1 of 2018.  Full Article

Aldeyra Therapeutics announces positive results from dry eye disease phase 2A clinical trial
Tuesday, 12 Sep 2017 07:01am EDT 

Sept 12 (Reuters) - Aldeyra Therapeutics Inc ::Aldeyra Therapeutics announces positive results from dry eye disease phase 2A clinical trial.  Full Article

Aldeyra Therapeutics Q2 loss per share $0.35
Tuesday, 8 Aug 2017 07:30am EDT 

Aug 8 (Reuters) - Aldeyra Therapeutics Inc :Aldeyra therapeutics announces second quarter 2017 financial results.Q2 loss per share $0.35.Q2 earnings per share view $-0.39 -- Thomson Reuters I/B/E/S.Aldeyra therapeutics inc - ‍ data from phase 2a clinical trial in dry eye disease expected to be announced in september 2017​.  Full Article

Aldeyra Therapeutics says last patient dosed in dry eye disease phase 2a clinical trial
Tuesday, 18 Jul 2017 08:00am EDT 

July 18 (Reuters) - Aldeyra Therapeutics Inc :Aldeyra Therapeutics announces last patient dosed in dry eye disease phase 2a clinical trial.Aldeyra Therapeutics Inc - ‍look forward to providing data from trial later this quarter​.  Full Article